<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00323804</url>
  </required_header>
  <id_info>
    <org_study_id>ANRS HC15 NRfi</org_study_id>
    <secondary_id>2005-002937-11</secondary_id>
    <nct_id>NCT00323804</nct_id>
  </id_info>
  <brief_title>Interest of Ribavirin in the Maintenance Treatment of Liver Fibrosis Using Low Dose Pegylated Interferon alpha2b in Patients With Chronic Hepatitis C Non Responders to Previous Antiviral Therapy.</brief_title>
  <official_title>Randomized, Double-blind, Placebo-controlled Multicenter Study Evaluating the Interest of a Long-term (3 Years) Treatment With Peginterferon Alfa-2b and Ribavirin on Liver Fibrosis in Non-responder Chronic Hepatitis C Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ANRS, Emerging Infectious Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ANRS, Emerging Infectious Diseases</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with chronic hepatitis C who did not respond to previous antiviral treatment develop&#xD;
      liver fibrosis leading to cirrhosis. Maintenance low dose pegylated interferon therapy of&#xD;
      fibrosis is currently under investigation in large multicenter trials. The aim of our study&#xD;
      is to assess if peginterferon alpha2b plus ribavirin is more efficient than peginterferon&#xD;
      alpha2b alone. 454 patients will be randomized between the 2 arms and the efficacy will be&#xD;
      assessed, after 3 years of treatment, on Metavir liver fibrosis score improvement.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Up to 45% of patients with chronic hepatitis C do not respond to pegylated&#xD;
      interferon/ribavirin combination therapy. These patients are prone to develop liver fibrosis&#xD;
      leading to cirrhosis and its complications. Interferon has proven to be efficient in liver&#xD;
      fibrosis treatment even in case of virological non response. Maintenance low dose pegylated&#xD;
      interferon therapy is currently under investigation in large multicenter trials. The aim of&#xD;
      our study is to assess wether peginterferon alpha 2 b (0.5 µg/kg/week) plus ribavirin&#xD;
      (800-1200 mg according to body weight) is more efficient than peginterferon alpha 2 b alone&#xD;
      in a long term 3 years treatment of liver fibrosis. 454 patients, non responders (VHC RNA&#xD;
      positive after 24 weeks of treatment or absence of ≥ 2 log HCV RNA drop after 12 weeks of&#xD;
      treatment) to a previous peginterferon/ribavirin antiviral treatment will be randomized&#xD;
      between the 2 arms, with a double-blind masking of ribavirin. The efficacy will be assessed&#xD;
      on Metavir liver fibrosis score improvement between pre and post therapeutic liver biopsy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of patients with at least a one point improvement in Metavir fibrosis score between the inclusion and the end-of-study liver biopsies.</measure>
    <time_frame>Screen visit and M36</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Distribution of the Metavir scoring on the end-of-study biopsy</measure>
    <time_frame>M36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of the Chevallier fibrosis score</measure>
    <time_frame>Screen visit and M36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of the area of fibrosis between the inclusion and the end-of -study biopsies</measure>
    <time_frame>Screen visit and M36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrosis serum markers</measure>
    <time_frame>Screen, day0, M6, M12, M24, M36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver elasticity before and after treatment</measure>
    <time_frame>Screen,M12, M24, M36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of treatment and quality of life</measure>
    <time_frame>day0, M6, M12, M24, M36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of occurrence of hepatic complications and/or liver transplantations</measure>
    <time_frame>Day 0 to M36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of the hepatitis C viral load</measure>
    <time_frame>Screen to M36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients with loss of detectable hepatitis C virus RNA</measure>
    <time_frame>Day 0 to M36</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">372</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <condition>Liver Fibrosis</condition>
  <arm_group>
    <arm_group_label>Randomised PegIFN alfa 2b + ribavirin (RBV) arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination of ribavirin capsules 200 mg, weight-based daily dose ( &lt;75 kg : 1000 mg ; ≥ 75 kg : 1200 mg), and low-dose PegIFN alfa 2b by subcutaneous injection 0.5 μg / kg / week, from day 0 to M36</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Randomised PegIFN alfa 2b + ribavirin-placebo arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Combination of ribavirin-placebo capsules 200 mg, weight-based daily dose ( &lt;75 kg : 1000 mg ; ≥ 75 kg : 1200 mg), and low-dose PegIFN alfa 2b by subcutaneous injection 0.5 μg / kg / week, from day 0 to M36</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Peginterferon alfa-2b</intervention_name>
    <description>PegIFN alfa 2b in addition to ribavirin or ribavirin-placebo, from day 0 to M36</description>
    <arm_group_label>Randomised PegIFN alfa 2b + ribavirin (RBV) arm</arm_group_label>
    <arm_group_label>Randomised PegIFN alfa 2b + ribavirin-placebo arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>Ribavirin in addition to PegIFN alfa 2b, from day 0 to M36</description>
    <arm_group_label>Randomised PegIFN alfa 2b + ribavirin (RBV) arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin-Placebo</intervention_name>
    <description>Ribavirin-placebo in addition to PegIFN alfa 2b, from day 0 to M36</description>
    <arm_group_label>Randomised PegIFN alfa 2b + ribavirin-placebo arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults over 18&#xD;
&#xD;
          -  With a hepatitis C virus infection (HCV RNA and anti-HCV antibodies in serum)&#xD;
&#xD;
          -  Not responders to a previous antiviral treatment using the interferon plus ribavirin&#xD;
             combination&#xD;
&#xD;
          -  With a wash-out of treatment for at least 6 months&#xD;
&#xD;
          -  With an active chronic hepatitis C and a Metavir fibrosis score ≥ 2&#xD;
&#xD;
          -  Serum ALT levels &gt; upper limit of the laboratory on two occasions within 6 months&#xD;
             before inclusion&#xD;
&#xD;
          -  Accepting to undergo a liver biopsy at the end of the study&#xD;
&#xD;
          -  Negative pregnancy test for women&#xD;
&#xD;
          -  With a social security cover&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of hepatic complications&#xD;
&#xD;
          -  History of transplantation&#xD;
&#xD;
          -  History of severe seizures&#xD;
&#xD;
          -  History of severe psychiatric disorders&#xD;
&#xD;
          -  Drug addiction within the last 12 months&#xD;
&#xD;
          -  Associated condition susceptible to be responsible for liver fibrosis&#xD;
&#xD;
          -  Hepatocellular carcinoma&#xD;
&#xD;
          -  Cardiovascular disease unstable under treatment&#xD;
&#xD;
          -  Uncontrolled diabetes&#xD;
&#xD;
          -  Retinopathy&#xD;
&#xD;
          -  Thyroid disease unstable under treatment&#xD;
&#xD;
          -  Epilepsy and/or central nervous system functional disorders&#xD;
&#xD;
          -  Autoimmune disease&#xD;
&#xD;
          -  Regular alcohol consumption&#xD;
&#xD;
          -  Pregnancy, breast-feeding or absence of contraception&#xD;
&#xD;
          -  Haemoglobin &lt;12 g/dl&#xD;
&#xD;
          -  platelets &lt;50000/mm3&#xD;
&#xD;
          -  Neutrophils &lt; 1200/ mm3&#xD;
&#xD;
          -  Severe hepatocellular failure (prothrombin index lower than 60%)&#xD;
&#xD;
          -  Renal failure (creatinine clearance lower than 50 mL/Mn)&#xD;
&#xD;
          -  Associated immunosuppressive drugs, corticosteroids, antiviral drugs (other than study&#xD;
             ones)&#xD;
&#xD;
          -  Treatment with drugs likely to have an effect on fibrosis&#xD;
&#xD;
          -  Anticonvulsants&#xD;
&#xD;
          -  Inability to tolerate interferon&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dominique Guyader, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Rennes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric Bellissant, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>CHU Rennes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Brugmann</name>
      <address>
        <city>Bruxelles</city>
        <zip>1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Bracops</name>
      <address>
        <city>Bruxelles</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Erasme</name>
      <address>
        <city>Bruxelles</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de Jolimont</name>
      <address>
        <city>La Louvière</city>
        <zip>7100</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Sart Tilman</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hépatogastroentérologie et d'endoscopie digestive - CH du Pays d'Aix</name>
      <address>
        <city>Aix en Provence</city>
        <zip>13616</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Nord</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hépatogastroentérologie - Hôpital Nord</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hépatologie - Gastroentérologie - Cancérologie digestive - CHU Angers</name>
      <address>
        <city>Angers</city>
        <zip>49100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Victor Dupouy</name>
      <address>
        <city>Argenteuil</city>
        <zip>95100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hépatogastroentérologie - Hôpital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d' Hépatogastroentérologie - Hôpital Jean Verdier</name>
      <address>
        <city>Bondy</city>
        <zip>93143</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hépatogastroentérologie et d'Assistance nutritive - Hôpital Haut-Lévêque</name>
      <address>
        <city>Bordeaux Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Pierre OUDOT</name>
      <address>
        <city>Bourgoin-Jallieu</city>
        <zip>38317</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hépatogastroentérologie - Hôpital de la Cavale Blanche</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hépatologie - Gastroentérologie - Nutrition -Hôpital de la Côte de Nacre</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Châteauroux</city>
        <zip>36000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hépatogastroentérologie - CHU d'ESTAING</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hépatogastroentérologie - Hôpital Beaujon</name>
      <address>
        <city>Clichy</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hépatogastroentérologie - CH Sud Francilien</name>
      <address>
        <city>Corbeil-Essonnes</city>
        <zip>91106</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hépatogastroentérologie - Hôpital du Bocage</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Nord</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hépatogastroentérologie - CH La Roche sur Yon</name>
      <address>
        <city>La Roche sur Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service des Maladies du Foie et de l'appareil Digestif - Hôpital de Bicêtre</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Département d'Hépatogastroentérologie - CH Le Mans</name>
      <address>
        <city>Le Mans</city>
        <zip>72037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hépatogastroentérologie - CHRU - Hôpital Claude Huriez</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hépatogastroentérologie - Hotel de la Croix Rousse</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hépatogastroentérologie - Hôpital Saint Joseph</name>
      <address>
        <city>Marseille</city>
        <zip>13285</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hépatogastroentérologie - CH Montauban</name>
      <address>
        <city>Montauban</city>
        <zip>82000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hépatogastroentérologie - CH Montélimar</name>
      <address>
        <city>Montelimar</city>
        <zip>26200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hépatogastroentérologie - Hôpital Saint Eloi</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hépatogastroentérologie - Hôtel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de l'Archet</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hépatogastroentérologie - Hôpital de la Source</name>
      <address>
        <city>Orléans</city>
        <zip>45067</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hépatogastroentérologie - Hôpital La Pitié Salpétrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hépatogastroentérologie - Hôpital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hépatogastroentérologie - Hôpital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hépatogastroentérologie - CHU Rouen</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Saint Quentin</city>
        <zip>02321</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hépatogastroentérologie, Clinique médicale B - Hôpital Civil</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hépatogastroentérologie - Hôpital Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hépatogastroentérologie - Hôpital Trousseau</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hépatogastroentérologie - Hôpital Brabois</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpita Paul Brousse</name>
      <address>
        <city>Villejuif</city>
        <zip>94804</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <study_first_submitted>May 9, 2006</study_first_submitted>
  <study_first_submitted_qc>May 9, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2006</study_first_posted>
  <last_update_submitted>September 3, 2014</last_update_submitted>
  <last_update_submitted_qc>September 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Maintenance therapy</keyword>
  <keyword>Non-responder patients</keyword>
  <keyword>Ribavirin/peginterferon combination therapy</keyword>
  <keyword>Hepatitis C, Chronic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2b</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

